Position in ABCL
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$234,934
+$210,380 QoQ
Shares Held
29,928
+687.4% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#86
of 150 holders
Holding Since
Mar 2021
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABCL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026State of Wyoming holds $40,938,454 across 171 Biotechnology names. ABCL ranks #43 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
35,525 | $4,027,114 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
8,698 | $2,478,669 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
4,767 | $1,771,750 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
9,446 | $1,769,046 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
11,780 | $1,350,812 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
2,410 | $1,294,049 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
48,794 | $1,234,488 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
2,768 | $926,698 |
All Filings in ABCL
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $234,934 | 29,928 | Shares | Sole | 2026-08-06 | |
| 2023-06-30 | $24,554 | 3,801 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $42,797 | 5,676 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $130,737 | 12,906 | Shares | Sole | 2023-02-15 | |
| 2022-09-30 | $95,329 | 9,639 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $9,467 | 889 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $6,581 | 675 | Shares | Sole | 2022-05-13 | |
| 2021-12-31 | $8,022 | 561 | Shares | Sole | 2022-02-11 | |
| 2021-09-30 | $11,843 | 591 | Shares | Sole | 2022-02-14 | |
| 2021-06-30 | $19,294 | 877 | Shares | Sole | 2022-02-14 | |
| 2021-03-31 | $16,063 | 473 | Shares | Sole | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||